Skip to main content

Table 2 Univariate Cox model analyses

From: Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

VariablesOSiPFS
HR95%CIpaHR95%CIpa
WBRT (Gy)
 none1.000 ref.1.000 ref.
  < 301.418(0.938–2.142)0.0981.713(1.133–2.588)0.011
 30–390.709(0.540–0.933)0.0140.694(0.533–0.904)0.007
  ≥ 400.616(0.483–0.785)< 0.0010.640(0.506–0.809)< 0.001
Local/boost RT (Gy)
 none1.000 ref.1.000 ref.
  < 500.722(0.422–1.234)ns0.977(0.608–1.572)ns
 50–590.575(0.436–0.759)< 0.0010.668(0.515–0.866)0.002
  ≥ 600.594(0.427–0.825)0.0020.566(0.409–0.783)< 0.001
SRT0.713(0.365–1.391)ns0.645(0.344–1.208)ns
Female0.761(0.627–0.924)0.0060.754(0.626–0.909)0.003
CVD0.970(0.801–1.175)ns1.039(0.863–1.250)ns
Age (years)
  < 501.000 ref.1.000 ref.
 50–591.051(0.783–1.412)ns0.889(0.673–1.174)ns
  ≥ 601.363(1.038–1.791)0.0521.169(0.904–1.512)ns
KPS
  < 701.000 ref.1.000 ref.
 70–800.920(0.718–1.178)ns0.918(0.722–1.166)ns
  ≥ 900.765(0.610–0.958)0.0200.842(0.676–1.047)ns
NSCLC history (month)
  < 10.910(0.710–1.167)ns1.023(0.805–1.299)ns
 1–61.153(0.834–1.595)ns1.410(1.030–1.931)0.032
 6–121.107(0.799–1.533)ns1.236(0.972–1.693)0.187
  > 121.000 ref.1.000 ref.
BM lesion number
 11.000 ref.1.000 ref.
 2–31.103(0.833–1.461)ns1.053(0.804–1.379)ns
  ≥ 41.118(0.907–1.377)ns1.099(0.898–1.344)ns
Extracranial met.1.244(0.988–1.565)0.0631.695(1.356–2.120)< 0.001
Brain stem met.2.185(1.226–3.896)0.0081.901(1.069–3.381)0.029
Meningeal met.1.212(0.853–1.723)ns1.501(1.063–2.119)0.021
Targeted therapy0.492(0.393–0.617)< 0.0010.597(0.484–0.736)< 0.001
Chemotherapy0.612(0.506–0.741)< 0.0010.791(0.659–0.951)0.013
BM resection
 none1.000 ref.1.000 ref.
 incomplete0.786(0.196–3.157)ns0.808(0.201–3.245)ns
 complete0.882(0.556–1.398)ns0.851(0.549–1.320)ns
Initial cTNM Stage IV1.027(0.829–1.271)ns1.106(0.901–1.357)ns
Lung tumor surgery
 none1.000 ref.1.000 ref.
 incomplete0.842(0.524–1.353)ns0.865(0.546–1.372)ns
 radical0.917(0.687–1.225)ns0.695(0.527–0.916)0.001
Adenocarcinoma0.809(0.659–0.993)0.0430.821(0.672–1.002)0.053
EGFR mutation
 neg.1.000 ref.1.000 ref.
 pos.0.670(0.484–0.927)0.0160.625(0.460–0.850)0.003
 no record1.195(0.931–1.534)0.1610.962(0.756–1.226)ns
ALK mutation
 neg.1.000 ref. 1.000 ref.
 pos.0.415(0.118–1.458)0.170 1.059(0.351–3.191)ns
 no record1.006(0.578–1.750)ns 1.109(0.663–1.857)ns
  1. OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; WBRT whole brain radiotherapy; ref. reference; RT radiotherapy; ns not significant with p > 0.20; SRT stereotactic radiotherapy; CVD cardiovascular disease; BM brain metastasis; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases; EGFR epidermal growth factor receptor; neg. Negative; pos. Positive; ALK anaplastic lymphoma kinase.
  2. a from the univariate Cox model analysis.